Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.

Clinical pharmacology and therapeutics - 1 Dec 2002

Rogers Janyce F, Morrison Ashley L, Nafziger Anne N, Jones Connie L, Rocci Mario L, Bertino Joseph S

Abstract excerpt

OBJECTIVES: Intravenous midazolam is used as an in vivo biomarker of hepatic cytochrome P450 (CYP) 3A activity. Midazolam is a central nervous system depressant and can produce cognitive impairment. The purpose of this study was 2-fold: (1) to determine whether administration of intravenous fluma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Anxiety Agents
Share to Area Under Curve
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Drug Interactions

Share to Infusions, Intravenous

Share to Midazolam

Share to Oxidoreductases, N-Demethylating

Source

Identifiers

PMID: 12496752
DOI: 10.1067/mcp.2002.128866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-12496752-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.PMID 12496752Read ↗

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.Semantic proximity Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

COGNITIVE ADVERSE EFFECTS OF LACOSAMIDE IN PATIENTS WITH LOCALIZATION RELATED EPILEPSY - A PROSPECTIVE OBSERVATIONAL STUDYSemantic proximity Read ↗

Tramadol-Induced Seizures in an Elderly Patient Without Comorbidities: A Case ReportSemantic proximity Read ↗

Reversal of delirium but induction of coma following flumazenil administration in multidrug intoxication suicide attempt involving quetiapine and medazepam: a case reportSemantic proximity Read ↗

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.Semantic proximity Read ↗

Hypnotic Doses of Fazamorexant Induced Less Impairment on Balance and Cognition Than Zolpidem in Healthy Adult and Elderly IndividualsSemantic proximity Read ↗

Massive tramadol ingestion resulting in fatal brain injury - a pharmacokinetic study with discussion on the involved mechanisms of toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.